Jabbor va boshqalarning fikriga ko'ra. Shvetsiyadagi Gyoteborg universiteti, faqat uchta kist suyuqligining biomarkerlariga asoslangan maqsadli mass-spektrometriya juda aniq aniqlay oladi va baholay oladi. imkoniyati oshqozon osti bezi kistalari pankreatik saraton . Ushbu eksperimental usul saraton kasalligini o'z vaqtida tashxislash, muvaffaqiyatli aralashish va saraton kasalligini oldini olishda yordam berishi mumkinligini tasdiqlash uchun boshqa tadqiqotlar o'tkazishga arziydi. (J Clin Oncol. Onlayn versiya 22 yil 2017 noyabr)
Cystic lesions of the pancreas are very common in imaging, and about half are pankreatik saraton lesions. Therefore, accurate and specific diagnosis is essential for the correct treatment of patients. Unfortunately, the currently used diagnostic methods cannot effectively distinguish between pancreatic precancerous lesions and malignant pancreatic cystic lesions.
Tadqiqotchilar tahlil qilish uchun an'anaviy ultratovushli endoskopiya rahbarligida ponksiyon natijasida olingan mukozal suyuqlik namunalaridan foydalanganlar. 24 bemorni olib borgan kohort tadqiqotida oqsil biologiyasining kashfiyot usuli malign transformatsiya va yuqori darajadagi displazi / saraton o'zgarishlari haqida ma'lumot bera oladigan 8 nomzod biomarkerni aniqladi. Keyinchalik, ma'lumotlar to'plamidagi 30 ta bemorga va tekshiruvlar to'plamidagi 80 ta bemorga 68 ta etiketlangan peptidlarning miqdoriy tahlili va parallel reaktsiyani kuzatish mass-spektrometriyasi o'tkazildi. Tadqiqotning yakuniy nuqtasi jarrohlik patologiyasi diagnostikasi yoki klinik kuzatuv natijasi bo'ldi.
The results show that the best markers for malignant tumors may be a group of peptides derived from MUC-5AC and MUC-2. These markers can identify precancerous lesions / malignant lesions from benign lesions. The accuracy is as high as 97%. Compared with the cystic liquid carcinoembryonic antigen and cytological detection of these standard identification methods, the accuracy of these standard methods is 61% (95% CI 46% ~ 74%, P <0.001) and 84% (95% CI 71% ~ 92%, P = 0.02). MUC-5AC combined with prostate stem cell antigen can identify high-grade dysplasia or cancer, with an accuracy of 96%, can detect 95% of malignant lesions or severe dysplasia, and the detection rate of carcinoembryonic antigen and cytology 35% and 50% respectively (P <0.001, P = 0.003).
